OXGENE helps solve the challenge of scalable manufacture for gene therapy. We have redeveloped the lentiviral plasmid system, resulting in yields greater than 1×10⁸ TU/ml. We have also generated manufacture-ready, suspension-mode lentiviral packaging cell lines to facilitate large scale lentiviral production.
Our technologies maximise process reproducibility and minimise manufacturing costs for some of the industry’s most exciting therapies.
Download the resource to continue reading.